Journal article
Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women
R Manchanda, S Patel, VS Gordeev, AC Antoniou, S Smith, A Lee, JL Hopper, RJ MacInnis, C Turnbull, SJ Ramus, SA Gayther, PDP Pharoah, U Menon, I Jacobs, R Legood
Journal of the National Cancer Institute | OXFORD UNIV PRESS INC | Published : 2018
DOI: 10.1093/jnci/djx265
Abstract
Background: The cost-effectiveness of population-based panel testing for high- and moderate-penetrance ovarian cancer (OC)/breast cancer (BC) gene mutations is unknown. We evaluate the cost-effectiveness of population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutation testing compared with clinical criteria/family history (FH) testing in unselected general population women. Methods: A decision-analytic model comparing lifetime costs and effects of criteria/FH-based BRCA1/BRCA2 testing is compared with BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing in those fulfilling clinical criteria/strong FH of cancer (<10% BRCA1/BRCA2 probability) and all women age 30 years or older. Analyses are presen..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
The study was funded by The Eve Appeal charity. The study is supported by researchers at the Barts Cancer Institute Cancer Research UK Centre for Excellence, Queen Mary University of London (C16420/A18066).